Next generation sequencing for biliary tract cancers

Click to increase image sizeClick to decrease image size

Declaration of interests

M.M Javle receives research/grant funding from QED, Novartis, Meclun, Arqule, Lilly; Honoraria: Taiho, Seattle Genetics and Merck. They also serve as an advisory/consultant for Orgimed, More Health and EDO. F Meric-Bernstam is a consultant for Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor and Zymeworks. Serves on the advisory committee for Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals and Zentalis. Receives research/grant funding from Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Millennium Pharmaceuticals Inc., Novartis, Puma Biotechnology Inc. and Taiho Pharmaceutical Co. She also receives honoraria from Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey, including non-financial support (Travel) from Beth Israel Deaconess Medical Center. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This work was funded by NIH grant 5T32CA009599-32 and the MD Anderson Cancer Center support grant P30 CA016672.